Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
This article was originally published in PharmAsia News
Executive Summary
The acquisition of Solvay's pharmaceutical unit, completed in February, gave Abbott a substantial branded generics business and strengthened its international presence. Now the company is looking to build on those assets with an enhanced emerging market strategy